BioVie Analyst Ratings
BioVie Analyst Ratings
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | Oppenheimer | → $12 | Reiterates | → Outperform |
| 09/28/2022 | 58.1% | EF Hutton | $14 → $8 | Maintains | Buy |
| 07/22/2022 | 38.34% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
| 03/17/2022 | 176.68% | EF Hutton | $9 → $14 | Maintains | Buy |
| 03/15/2022 | 77.87% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 433.6% | B. Riley Securities | $50 → $27 | Maintains | Buy |
| 01/15/2021 | 828.85% | B. Riley Securities | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | 奥本海默 | →$12 | 重申 | →跑赢大盘 |
| 09/28/2022 | 58.1% | EF Hutton | $14→$8 | 维护 | 买 |
| 07/22/2022 | 38.34% | 康托·菲茨杰拉德 | →$7 | 开始承保 | →超重 |
| 03/17/2022 | 176.68% | EF Hutton | $9→$14 | 维护 | 买 |
| 03/15/2022 | 77.87% | 奥本海默 | →$9 | 开始承保 | →跑赢大盘 |
| 2021年11月30日 | 433.6% | B.莱利证券 | $50→$27 | 维护 | 买 |
| 2021/01/15 | 828.85% | B.莱利证券 | →$47 | 开始承保 | →购买 |
What is the target price for BioVie (BIVI)?
BioVie(BIVI)的目标价格是多少？
The latest price target for BioVie (NASDAQ: BIVI) was reported by Oppenheimer on February 14, 2023. The analyst firm set a price target for $12.00 expecting BIVI to rise to within 12 months (a possible 137.15% upside). 5 analyst firms have reported ratings in the last year.
奥本海默于2023年2月14日报道了BioVie(纳斯达克：BIVI)的最新目标价。这家分析公司将目标价定为12美元，预计BIVI将在12个月内升至(可能上涨137.15%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for BioVie (BIVI)?
BioVie(BIVI)的最新分析师评级是多少？
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Oppenheimer, and BioVie reiterated their outperform rating.
奥本海默提供了对BioVie(纳斯达克代码：BIVI)的最新分析师评级，BioVie重申了其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
BioVie(BIVI)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与BioVie的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。BioVie的上一次评级是在2023年2月14日提交的，所以你应该预计下一次评级将在2024年2月14日左右提供。
Is the Analyst Rating BioVie (BIVI) correct?
分析师对BioVie(BIVI)的评级正确吗？
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的BioVie(BIVI)评级被重申，目标价在0.00美元至12.00美元之间。BioVie(BIVI)目前的交易价格为5.06美元，在分析师的预测范围内。
